SEC Filing | Company/Stock | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Gain/Loss |
---|---|---|---|---|---|---|---|---|
22-Jul-20 5:39 PM View: | Meiragtx Holdings Plc (MGTX) | 20-Jul-20 | Market Sale (Planned) | 6,667 | $15.00 | $100,005.00 | (4%) 164.14K to 157.48K | (9%) |
13-May-20 5:37 PM View: | Meiragtx Holdings Plc (MGTX) | 11-May-20 | Market Sale (Planned) | 2,184 | $15.00 | $32,760.00 | (1%) 166.33K to 164.14K | (9%) |
22-Apr-20 5:00 PM View: | Meiragtx Holdings Plc (MGTX) | 20-Apr-20 | Market Sale (Planned) | 4,482 | $15.00 | $67,230.00 | (3%) 170.81K to 166.33K | (9%) |
22-Dec-15 5:32 PM View: | Vical Inc. (FRTX) | 18-Dec-15 | Grant | 10,000 | $0.01 | $100.00 | 100% 0 to 10.0K | |
04-Nov-09 9:06 PM View: | Merck & Co. Inc. (MRK) | 03-Nov-09 | Disposition | 1,000 | -- | -- | (100%) 1.0K to 0 | |
05-Nov-09 9:36 PM View: | Schering-Plough Corp. (MRK) | 03-Nov-09 | Grant | 1,000 | -- | -- | 100% 0 to 1.0K | |
16-Oct-09 3:36 PM View: | Cell Genesys, Inc. (CEGE) | 14-Oct-09 | Disposition | 32,000 | -- | -- | (100%) 32.0K to 0 | |
09-Apr-09 4:02 PM View: | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Payment of Exercise | 27,927 | $19.94 | $556,864.00 | (44%) 63.5K to 35.57K | (< 1%) |
09-Apr-09 4:02 PM View: | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Option Exercise | 7,500 | $19.91 | $149,325.00 | 13% 56.0K to 63.5K | < 1% |
09-Apr-09 4:02 PM View: | CV Therapeutics, Inc. (CVTX) | 07-Apr-09 | Option Exercise | 27,500 | $11.08 | $304,625.00 | (77%) 35.57K to 8.07K | (80%) |
01-Jul-08 4:25 PM View: | Cell Genesys, Inc. (CEGE) | 30-Jun-08 | Grant | 4,000 | -- | -- | 14% 28.0K to 32.0K | |
03-Jul-07 1:09 PM View: | Cell Genesys, Inc. (CEGE) | 29-Jun-07 | Grant | 4,000 | -- | -- | 17% 24.0K to 28.0K | |
15-Mar-05 1:58 PM View: | CV Therapeutics, Inc. (CVTX) | 14-Mar-05 | Market Purchase | 1,000 | $20.36 | $20,360.00 | 100% 0 to 1.0K | (2%) |
15-Mar-05 2:00 PM View: | CV Therapeutics, Inc. (CVTX) | 14-Mar-05 | Market Purchase Duplicate | 1,000 | $20.36 | $20,360.00 | 100% 0 to 1.0K | (2%) |